December 18, 2017 / 1:45 PM / 6 months ago

BRIEF-EyeGate Achieves 75 Pct Enrollment In Pivotal Phase 3 Clinical Trial For Anterior Uveitis Triggering Milestone Payment

Dec 18 (Reuters) - EyeGate Pharmaceuticals Inc:

* EYEGATE ACHIEVES 75% ENROLLMENT IN PIVOTAL PHASE 3 CLINICAL TRIAL FOR ANTERIOR UVEITIS TRIGGERING MILESTONE PAYMENT

* EYEGATE PHARMACEUTICALS INC - TOPLINE DATA IS EXPECTED TO BE RELEASED IN Q2 OF 2018.

* EYEGATE PHARMA - REMAIN ON-TRACK TO REPORT TOPLINE DATA FROM TRIAL IN Q2 2018, WITH EXPECTED NDA FILING FOR EGP-437 IN ANTERIOR UVEITIS NEXT YEAR Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below